AQUEOUS PHARMA
HOME
FRESHKOTE
INNOVATIVE THERAPY FOR DRY EYE
   

UTILIZING DR. FRANK HOLLY'S UNPRECEDENTED KNOWLEDGE OF THE HUMAN TEAR FILM and OCULAR SURFACE

Aqueous Pharma was founded by Joe Echols, to focus on innovative therapy for dry eye syndrome on a global basis. Assets include the 3 original artificial tear products & the patented ophthalmic solution preservative developed by Dr. Frank J. Holly, and Aqueous has developed a new tear product, FRESHKOTE, reviewed on page 2 of this site.

BREAKING NEWS:   APL-106 DEVELOPED AS NEW TEAR STIMULATION /ENHANCEMENT PRODUCT.   PATENT FILED IN THE USA.  SEE: WWW.ARTIFICIALTEARS.NET for more details

Effective Artificial Tears Should Have:

  • Low Viscosity
  • High Oncotic Pressure (~65mmHg) except for mild dry eye
  • Appropriate Synergistic Blending of Polymers
  • Added Nutrients or other components depending on etiology of Dry Eye type
  • Effective and Non-Irritating Preservative for multidose or non-preserved for unit of use
Dry eye is the most frequently diagnosed ocular disorder worldwide. Artificial tear products are front line therapy for this condition with this market showing growth of over 20% annually. Other tear products do not address healing of the ocular surface and only provide a temporary relief of symptoms; thereby providing the motivation for Aqueous Pharma to develop uniquely effective formulations.

All 4 tear formulations are the first to enhance wettability of ocular surface cells. NUTRATEAR, containing Vitamin B12, is for mild dry eye/overuse of computers. DAKRINA has been found effective in mucin-deficient dry eye due to its polymer-solubilized vitamin A; bio-available to the ocular surface and DAKRINA is the only tear clinically shown to increase goblet cell density in Sjogren's syndrome patients in a study at Duke University by Dr. Gary Foulks. 

All formulations are in compliance with the FDA Ophthalmic Monograph. FreshKote, Dakrina & Dwelle have been cleared for OTC Marketing in the UK by the MHRA (British Regulatory Authority). FRESHKOTE (code: APL-105) was approved in all European Union Countries in November 2006 via CE Mark. All 4 tears are preserved with the highly effective but yet totally non-irritating preservative, polyquaternium-42 (also known as polixetonium). NutraTear, Dakrina & Dwelle are Dr. Holly's original (core) products. More information on FreshKote is on page 2 of this site and at www.freshkote.comFRESHKOTE is exclusively marketed in the USA by FOCUS Laboratories of North Little Rock, Arkansas - ph: 1-501-753-6006.